Sort:
Open Access Rapid Communication Issue
Targeting BMI1 mitigates chemoresistance in ovarian cancer
Genes & Diseases 2022, 9 (6): 1415-1418
Published: 18 March 2022
Abstract PDF (1.2 MB) Collect
Downloads:6
Open Access Corrigendum Issue
Corrigendum to ‘Bmi-1: At the crossroads of physiological and pathological biology’ [Genes & Diseases 2 (2015) 225–239]
Genes & Diseases 2015, 2 (4): 353
Published: 08 December 2015
Abstract PDF (254.4 KB) Collect
Downloads:1
Open Access Review Article Issue
Bmi-1: At the crossroads of physiological and pathological biology
Genes & Diseases 2015, 2 (3): 225-239
Published: 05 May 2015
Abstract PDF (734.7 KB) Collect
Downloads:1

Bmi-1 is a member of the Polycomb repressor complex 1 that mediates gene silencing by regulating chromatin structure and is indispensable for self-renewal of both normal and cancer stem cells. Despite three decades of research that have elucidated the transcriptional regulation, post-translational modifications and functions of Bmi-1 in regulating the DNA damage response, cellular bioenergetics, and pathologies, the entire potential of a protein with such varied functions remains to be realized. This review attempts to synthesize the current knowledge on Bmi-1 with an emphasis on its role in both normal physiology and cancer. Additionally, since cancer stem cells are emerging as a new paradigm for therapy resistance, the role of Bmi-1 in this perspective is also highlighted. The wide spectrum of malignancies that implicate Bmi-1 as a signature for stemness and oncogenesis also make it a suitable candidate for therapy. Nonetheless, new approaches are vitally needed to further characterize physiological roles of Bmi-1 with the long-term goal of using Bmi-1 as a prognostic marker and a therapeutic target.

Total 3